fashion -WSS

fashion

author：fashion 2025-09-04 05:35:58 - browse：472

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

WSS

Medicare isn't yet testing food as medicine

CDC panel: People 65 and older should get a Covid spring booster shot

Inequities make cancer less preventable for women: report

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Pfizer is about to make a big push in cancer. Will investors listen?

Pfizer is about to make a big push in cancer. Will investors listen?

Wikipedia

fashion

explore

Medicare proposal to cover medical devices draws a mixed reaction

Inequities make cancer less preventable for women: report

DIEP, the 'gold standard' of breast reconstruction, is under threat

Researchers use wearables data and AI to predict preterm birth risk

Tori Bowie and the unacceptable rates of Black maternal death

NEJM study measures Covid brain fog, impact on IQ

Hepatitis C has a cure — but many Americans still lack access to it

5 ways to address the shortage of health care workers

Malaria cases in Florida and Texas: Here’s what you need to know

Study fuels hope CAR

entertainment

Are embryos people? Reproductive medicine's future depends on the answer

WHO recommends dropping component of many flu vaccines

Laying a path for careers in science

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Address the ethical violations that led to 'Three Identical Strangers'

Mindstrong's demise and the future of mental health care

knowledge

explore

focus

focus